Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hormone boost plus chemo aims to shrink hard-to-treat prostate cancer

NCT ID NCT03522064

Recruiting now Disease control Sponsor: St Vincent's Hospital, Sydney Source: ClinicalTrials.gov ↗

First seen May 01, 2026 · Last updated Jun 12, 2026 · Updated 9 times

Summary

This study tests whether a high dose of testosterone combined with the chemotherapy drug carboplatin can help men with a specific type of advanced prostate cancer that has stopped responding to standard hormone therapy. About 30 men with a genetic defect called homologous recombination deficiency will receive the treatment. The goal is to see if this approach can lower PSA levels and slow cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kinghorn Cancer Centre, St. Vincent's Hospital

    RECRUITING

    Sydney, New South Wales, 2010, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CASTRATION-RESISTANT PROSTATE CANCER HOMOLOGOUS RECOMBINATION DEFICIENCY

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER